Skip to content

Detection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children

Detection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02809560
Acronym
CAVASTHME
Enrollment
60
Registered
2016-06-22
Start date
2013-03-31
Completion date
2016-05-31
Last updated
2016-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Lymphocytes Th2, Cav1 channels

Brief summary

Asthma affects about 10% of children and 6% of adults in industrialized countries. Lymphocytes (L) Th2, a T cell population (LT) producing interleukin (IL) -4, 5 and 13 are broadly involved in this pathology in experimental models and in humans. Many studies show that the signaling pathways activated by the commitment of T receiver differ depending LT. The identification of specific signaling pathways links to Th2 offer new therapeutic approaches. Precedent study showed that mouse Th2 selectively expressed related to calcium channels sensitive channels Cav1 voltage, normally found in excitable cells where they are defined as receivers dihydropyridine (DHP). The goal of the present study is to show the presence of Cav1 channels in inflammatory cells in allergic asthmatics and show overexpression of these channels in the peripheral blood mononuclear cells from asthmatic subjects before and / or after stimulation with the TCR in comparison with controls.

Interventions

PROCEDUREInduced sputum method using hypertonic serum

Collection of expectoration in sterile vial, conserved in ice all along the examination

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

For Asthmatic children arm : * Girl not in childbearing potential or taking contraceptive treatment * Asthma diagnosis in at least 6 months as defined by clinical symptoms (expiratory dyspnea, wheezing, sibilance) and respiratory function (reversibility of VEMS at least 12% after salbutamol administration) * Allergologic tests positives to airborne allergens : positive prick test and/or specific IgE \> 0,35 kU/L for at least one allergen * Asthma severity between mild to moderate based on Global initiative for asthma classification during more than one month with inhaled corticotherapies +/- long term action beta -mimetic long compounds (salmeterol, formoterol) * Patient insured with a social security scheme For control children arm : * Girl not in childbearing potential or taking contraceptive treatment * No medical history of asthma * No medical history of allergy or symptoms of allergy on skin (atopic dermatitis), respiratory tract (rhino-conjunctivitis, asthma) or food allergy

Exclusion criteria

For both arms: * Chronic respiratory pathology : known occlusive or restrictive respiratory syndrome like interstitial lung disease, neuromuscular disease, mucoviscidoses, respiratory tract abnormalities with cough, dyspnea or digital hippocratism. * History of pulmonary or nose and throat infectious disease during last 4 months * Parasitic disease non treated during last 3 months * Dyspnea during the inclusion * Systemic corticotherapy during the last 3 months before inclusion * Immunosuppressive therapy during the last 3 months before inclusion * Diabeta * Disease causing immune disorder * Infection during inclusion * Participation to another study witch implies medical treatment during last 3 months before inclusion For asthmatic children arm : * Chronic pulmonary pathology (excluding asthma) * Asthma exacerbation during inclusion * VEMS \< 70% of normal range or VEMS \< 70% of normal range after inhalation of serum (despite salbutamol administration) * Patient unable to complete pulmonary function testing

Design outcomes

Primary

MeasureTime frame
Detection of sequence coding for Cav1 in cells as assessed by reverse transcription polymerase chain reactionDay 1

Secondary

MeasureTime frame
Presence of Cav1 channels as assessed by correlation between Cav1 expression and eosinophils in expectoration collectionDay 1
Presence of Cav1 channels as assessed by correlation between Cav1 expression and lymphocytes T in expectoration collectionDay 1
Comparison of CRTH2+ cells in total blood between asthmatic and control groupDay 1
Comparison of Cav1 channels and cytokines Th2 expression between asthmatic and control group before T-Cell receptor stimulationDay 1
Comparison of Cav1 channels and cytokines Th2 expression between asthmatic and control group after T-Cell receptor stimulationDay 1

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026